| Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis S Satapathy, BR Mittal, A Bhansali Clinical Endocrinology 91 (6), 718-727, 2019 | 81 | 2019 |
| Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis S Satapathy, H Singh, R Kumar, BR Mittal American Journal of Roentgenology 216 (3), 599-607, 2021 | 60 | 2021 |
| Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis S Satapathy, A Sood, CK Das, BR Mittal Prostate Cancer and Prostatic Diseases 24 (3), 880-890, 2021 | 50 | 2021 |
| 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis S Satapathy, BR Mittal Nuclear medicine communications 40 (12), 1195-1203, 2019 | 37 | 2019 |
| Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects S Satapathy, N Das, D Bandyopadhyay, SC Mahapatra, DS Sahu, ... Indian Journal of Clinical Biochemistry 32, 357-363, 2017 | 37 | 2017 |
| Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177 Lu-Labeled Prostate-Specific Membrane … S Satapathy, BR Mittal, A Sood Clinical Nuclear Medicine, 2020 | 35 | 2020 |
| Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial S Satapathy, D Bandyopadhyay, BK Patro, S Khan, S Naik Complementary therapies in medicine 53, 102526, 2020 | 33 | 2020 |
| 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial S Satapathy, BR Mittal, A Sood, CK Das, RS Mavuduru, S Goyal, J Shukla, ... European Journal of Nuclear Medicine and Molecular Imaging, 1-11, 2022 | 31 | 2022 |
| Health‑Related Quality‑of‑Life Outcomes with Actinium‑225‑Prostate‑Specific Membrane Antigen‑617 Therapy in Patients with Heavily Pretreated Metastatic Castration‑Resistant … S Satapathy, BR Mittal, A Sood, CK Das, SK Singh, RS Mavuduru, ... Indian Journal of Nuclear Medicine 35 (4), 299-304, 2020 | 21 | 2020 |
| Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors S Satapathy, BR Mittal, A Sood, A Sood, R Kapoor, R Gupta Clinical Nuclear Medicine, 2020 | 18 | 2020 |
| Clinical determinants of severe COVID-19 disease–a systematic review and meta-analysis AK Sahu, R Mathew, P Aggarwal, J Nayer, S Bhoi, S Satapathy, M Ekka Journal of Global Infectious Diseases 13 (1), 13-19, 2021 | 16 | 2021 |
| 18F-FDG PET/CT in tuberculosis: can interim PET/CT predict the clinical outcome of the patients? A Sood, BR Mittal, M Modi, R Chhabra, R Verma, N Rana, AS Parihar, ... Clinical nuclear medicine 45 (4), 276-282, 2020 | 16 | 2020 |
| Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: A single-centre experience S Satapathy, BR Mittal, A Sood, R Verma, N Panda Nuclear Medicine Communications 41 (7), 629-635, 2020 | 14 | 2020 |
| Response to concomitant enzalutamide and 177Lu-PSMA-617 radioligand therapy in ATM-mutated metastatic castration resistant prostate cancer S Satapathy, CK Das, AS Parihar, A Sood, BR Mittal Clinical nuclear medicine 46 (7), 582-583, 2021 | 11 | 2021 |
| Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis S Satapathy, C Bal Journal of Pediatric Endocrinology and Metabolism 35 (6), 749-760, 2022 | 10 | 2022 |
| 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 … S Satapathy, BR Mittal, A Sood, A Sood, R Kapoor, R Gupta, D Khosla JCO Global Oncology 7, 1167-1175, 2021 | 9 | 2021 |
| Delayed nephrotoxicity after 225Ac-PSMA-617 radioligand therapy S Satapathy, A Sharma, A Sood, P Maheshwari, HJS Gill Clinical Nuclear Medicine 47 (6), e466-e467, 2022 | 8 | 2022 |
| Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant … S Ballal, MP Yadav, S Satapathy, S Raju, M Tripathi, NA Damle, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (12), 3777-3789, 2023 | 7 | 2023 |
| [177Lu] Lu-PSMA-radioligand therapy efficacy outcomes in taxane-naïve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review … S Satapathy, RK Sahoo, C Bal Journal of Nuclear Medicine 64 (8), 1266-1271, 2023 | 7 | 2023 |
| Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (177Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors S Satapathy, A Bhattacharya, A Sood, R Kapoor, R Gupta, A Sood, ... Cancer Biotherapy & Radiopharmaceuticals 37 (1), 23-29, 2022 | 7 | 2022 |
Bhagwant Rai MittalProfessor of Nuclear MedicineVerified email at pgimer.edu.in
